Overview

Basal Cell Carcinomas Treated With Ablative Fractional Laser and Ingenol Mebutate

Status:
Completed
Trial end date:
2018-05-18
Target enrollment:
Participant gender:
Summary
A prospective clinical, uncontrolled, open-label, explorative phase 2a trial on patients with histologically-confirmed superficial and nodular basal cell carcinoma (BCC). The study assesses tolerability and tumor clearance after laser-assisted topical delivery of topical ingenol mebutate.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Merete Haedersdal
Collaborator:
LEO Pharma